Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10-Reference-Cited by-同舟云学术

Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10

Published:2023-02 Issue: Volume:555 Page:216025
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Yang Jing,Hou Changchun,Wang Huashan,Perez Edith A.,Do-Umehara Hanh Chi,Dong Huali,Arunagiri Vinothini,Tong Fangjia,Van Scoyk Michelle,Cho Minsu,Liu Xinyi,Ge Xiaodong,Winn Robert A.,Ridge Karen M.,Wang Xiaowei,Chandel Navdeep S.,Liu Jing^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference56 articles.

1. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer;Kim;Nature,2016

2. Synthetic lethal vulnerabilities in KRAS-mutant cancers;Aguirre;Cold Spring Harb Perspect Med,2018

3. Lung cancer;Herbst;N. Engl. J. Med.,2008

4. Non-small-cell lung cancers: a heterogeneous set of diseases;Chen;Nat. Rev. Cancer,2014

5. Non-small-cell lung cancer;Gridelli;Nat. Rev. Dis. Prim.,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of interferon α and γ response by Huwe1-mediated Miz1 degradation promotes SARS-CoV-2 replication;Frontiers in Immunology;2024-07-05

2. YAP1-activated ZNF131 promotes hepatocellular carcinoma cell proliferation through transcriptional regulation of PAIP1;Archives of Biochemistry and Biophysics;2024-04

3. Aptamer AS411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer;RSC Medicinal Chemistry;2024

4. The role of Pcdh10 in neurological disease and cancer;Journal of Cancer Research and Clinical Oncology;2023-04-14